We provide advanced data, statistical and economic analysis to support health technology assessment, pricing, payer and policy decisions in pharmaceutical, biotech and medtech markets. Our work is grounded in evaluator-informed frameworks and designed to be transparent, defensible and decision-ready.

This service is an integral part of reimbursement strategy, evidence planning, market access submissions and funding arguments — where rigorous analysis must translate into actionable insights, not just technical outputs.

Decision Context

Data and analytical evidence underpin critical decisions at every stage of the market access and reimbursement pathway. Whether it is quantifying comparative effectiveness, estimating the economic value of interventions, or forecasting budget impact, these analyses directly influence how PBAC, MSAC, payers and policymakers judge value and affordability.

In complex funding environments, analytical rigor alone is not enough — insights must be communicated in a way that aligns with decision-maker expectations and real-world constraints.

Our Role

Pulse Economics partners with sponsors, research organisations and health agencies to transform data into decision-relevant evidence.

We bridge the gap between technical modelling and strategic interpretation, ensuring that analysis answers key questions, supports value narratives, and anticipates scrutiny from HTA bodies and payers. Our work draws on deep analytical expertise and strong health economics grounding, enabling clients to navigate complex evidence landscapes with confidence.

What We Deliver in Practice

We tailor our analytical services to the decision context of your product or policy case, including:

Economic, Financial & Outcomes Modelling

• Cost-effectiveness and cost-utility analysis, including Markov cohort models
• Patient-level microsimulation models to reflect heterogeneity, pathway complexity and long-term outcomes
• Budget impact modelling for PBS, MBS and Prescribed List submissions
• Financial forecasting of uptake, utilisation and expenditure under alternative scenarios
• Scenario, threshold and sensitivity analyses to support pricing and reimbursement decisions

Comparative Effectiveness & Evidence Synthesis

• Systematic evidence synthesis
• Network meta-analysis and indirect treatment comparisons
• Evidence triangulation to strengthen HTA and payer narratives

Survival & Real-World Data Modelling

• Parametric and semi-parametric survival analysis
• Extrapolation strategies aligned with HTA expectations
• Real-world evidence (RWE) modelling to supplement clinical data

Statistical & Predictive Analysis

• Advanced statistical modelling to understand variability and uncertainty
• Sensitivity testing and probabilistic analysis
• Predictive models supporting policy evaluation, forecasting and strategy

Our Approach

Our analytical work is defined by three core principles:

1. Evaluator-Informed Interpretation

We understand how analytical outputs are reviewed in PBAC, MSAC and other HTA processes — including where models are stress-tested, how uncertainty is valued, and what narratives matter most.

2. Strategic Integration

Analysis is never done in isolation. We connect analytical findings to evidence strategy, pricing insights and submission planning, ensuring results inform decisions rather than simply describe data.

3. Transparency & Defensibility

All models and statistical approaches are documented with clear assumptions, rationale and decision logic — ensuring committees, payers and policymakers can follow and trust the evidence.

Managing Uncertainty & Communication

Decision-makers focus on uncertainty — whether around long-term outcomes, real-world performance or comparative value. We explicitly address uncertainty through:

• Scenario analysis and sensitivity testing
• Probabilistic frameworks
• Clear visualisation and narrative interpretation

Our reports and briefings do more than present numbers. They explain what the results mean for decisions, risk mitigation and value claims.

Where This Service Applies

Our analytical services support decisions across:

• Pre-submission planning and evidence gap analysis
• HTA submissions (PBS, MBS, Prescribed List, Life Saving Drugs Program)
• Pricing strategy and payer negotiation
• Policy evaluation and public funding proposals
• Post-decision monitoring and real-world evidence generation

We work with early-stage innovators and established sponsors, tailoring analytical depth and communication style to the audience and decision platform.

Why Pulse Economics

• Rigorous analytical expertise paired with evaluator-level insight
• Deep understanding of how PBAC, MSAC and payer bodies interpret evidence
• Integrated economic, statistical and strategic thinking
• Practical experience across pharmaceutical, biotech and medtech markets

Our clients benefit from analysis that is accurate, strategic and aligned to real decision needs, not just technically sound.

---

---

---